Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewOncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications.Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.Two Antagonistic MALT1 Auto-Cleavage Mechanisms Reveal a Role for TRAF6 to Unleash MALT1 Activation.A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis.Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.The molecular biology of diffuse large B-cell lymphoma.Doubling down on PKC benefits allogeneic BMT.EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivoEnzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies.Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictionsDiffuse large B-cell lymphoma-treatment approaches in the molecular era.Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies.Protein kinase C inhibitors for immune disorders.Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.Protein kinase C in cellular transformation: a valid target for therapy?Genetic and molecular targets in lymphoma: implications for prognosis and treatment.The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.Targeting of B-cell receptor signalling in B-cell malignancies.Targeting protein kinase C in mantle cell lymphoma.Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model.Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition.[Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].Global gene expression changes of in vitro stimulated human transformed germinal centre B cells as surrogate for oncogenic pathway activation in individual aggressive B cell lymphomasAttacking MALT1 for ABC-DLBCL therapy.Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders.
P2860
Q27304386-25FAB258-1500-429D-B0FC-5202B2A09465Q30375911-A6BD560C-F858-4B90-ACC5-E6C30BE42711Q33622342-E606D107-CA37-47F8-B74E-F543C3141BD2Q33889168-A1E13730-EDB6-4D9F-A881-8642242D00C8Q34096861-04C07E78-A27D-460A-8988-6A08AFCE7591Q34106863-ECA2CE04-FCAC-4500-A83E-4939007A787AQ35018336-08EFE343-E4E5-42D1-9452-10761E528560Q35818443-6927A7BE-5B3B-4F64-AB2E-0DB1AD0963EEQ35915107-58DECCD0-33CC-4C26-9FB9-96B7F20257EEQ36021623-67D475DC-D137-47E2-A2F4-88CFD8B9C751Q36239551-EA5AB1A6-A1AC-4BE4-A118-91723297B8B7Q36244135-3EFBDE86-1F38-458F-82BE-B9267F4ADDFEQ36546004-814D5BD5-C789-4A75-B927-80C0F1D2BD77Q36612630-7E7824EB-15FB-4E76-B039-772B4F0746F1Q37215114-A7251DC4-3114-4FA9-B2FA-5A789C9235C0Q37235726-FBE3D62F-C525-48C3-ADD8-0DB40D09C1F3Q37699271-4560FEF5-5A1F-40CD-BC5A-7BDA5B5A559AQ37884624-69149461-C5C3-4862-BAAE-CCCF4C3D7A46Q38022591-DEB992DF-F977-4D2A-9C89-F2417C25D0B1Q38161760-66572EDF-884A-43D0-84C1-4BF01FD2997AQ38179500-BA75255B-9C03-4483-B02E-1E1B0D8715E5Q38182355-B362FD98-03D0-429B-8BDC-8077695B822AQ38217280-BE21CA64-5D64-4880-81BB-D1C6B75A0260Q38240579-911FF9E1-2D69-4364-8E41-32C37061EF1DQ38268442-440C1128-B509-4A66-A497-77E5EC3D29ACQ38294626-F0961E75-B328-4A0C-9345-550DC55AE846Q38664822-B1360601-6328-4A6F-8AC4-8D23908FE0FAQ38744922-D69BC453-681C-4495-8EE6-58B6518786C1Q38791124-454255B9-5733-45EC-9B07-6B81486ABD68Q38798340-743743E8-6EA2-463C-8A15-9F858C3B8B92Q38833742-C7ECA27D-2D84-4CEF-A038-3DB7B67FA371Q38988815-E3752D7C-7CAD-4E68-A287-633F3E39A7CEQ38994639-20EBB0FD-A278-4260-903A-A3A869780E26Q38994711-AA290EC4-03CF-4D56-A05A-667FEEEF7D12Q40080582-0CDCEA81-E5CF-482F-A545-51F12DF6045AQ42005623-A0A13C4F-122D-4878-AF9D-8CDF458523C1Q43127403-1CAFE673-1BA4-40EB-9627-24E87C32A93EQ44335401-B64F8C2D-F99E-4688-AA60-DC9AAEE6B87AQ44707208-D065EBD4-2269-4978-AE3E-08C99EB0933CQ47131231-04341D26-4851-4ECE-A151-88FCBB3B7359
P2860
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Protein kinase C inhibitor sot ...... iffuse large B-cell lymphomas.
@en
Protein kinase C inhibitor sot ...... iffuse large B-cell lymphomas.
@nl
type
label
Protein kinase C inhibitor sot ...... iffuse large B-cell lymphomas.
@en
Protein kinase C inhibitor sot ...... iffuse large B-cell lymphomas.
@nl
prefLabel
Protein kinase C inhibitor sot ...... iffuse large B-cell lymphomas.
@en
Protein kinase C inhibitor sot ...... iffuse large B-cell lymphomas.
@nl
P2093
P1433
P1476
Protein kinase C inhibitor sot ...... iffuse large B-cell lymphomas.
@en
P2093
Andreas Enns
Bernd Dörken
Frank Stegmeier
Georg Lenz
Huaping Tang
Liqing Chen
Markus Warmuth
Peter Lenz
Tara L Naylor
P304
P356
10.1158/0008-5472.CAN-10-2525
P407
P577
2011-02-15T00:00:00Z